Loading

Study: Cannabidiol Holds Promise For Treating Psychosis

Thursday, 19 December 2013

Study: Cannabidiol Holds Promise For Treating Psychosis

Utrecht, The Netherlands: Cannabidiol (CBD), a non-psychotropic cannabinoid, alleviates psychotic symptoms and may hold promise as an alternative antipsychotic treatment, according to a review published in the November issue of the journal Neuropsychopharmacology.

Investigators in the Netherlands and in the United Kingdom reviewed preclinical and clinical data on the use of CBD as an antipsychotic agent. Authors reported that both animal and human studies document the ability of CBD to mitigate symptoms of psychosis. Specifically, CBD administration is associated with improved symptoms in clinical evaluations of patients with schizophrenia, Parkinson's disease, and ketamine-induced dissociative and psychotic symptoms.

Investigators also highlighted a 2012 double-blind, randomized placebo-controlled trial assessing CBD versus the prescription anti-psychotic drug amisulpride in 42 subjects with schizophrenia and acute paranoia. Authors reported that both CBD and the prescription drug were associated with "equally significant clinical improvement" in this patient population, but that cannabidiol "possessed significantly less side effects."

They concluded: "[E]vidence from several study domains suggests that CBD has some potential as an antipsychotic treatment. ... Given the high tolerability and superior cost-effectiveness, CBD may prove to be an attractive alternative to current antipsychotic treatment."

Previous human trials assessing the administration of CBD in healthy human subjects report that the cannabinoid is "safe and well tolerated."

Separate investigations of CBD, primarily in animal models, have documented the cannabinoid to possess a variety of therapeutic qualities, including anti-inflammatory, anti-diabetic, anti-epileptic, anti-cancer, and bone-stimulating properties. Recently, the FDA approved the experimental use of CBD extracts for the treatment of a rare form of intractable pediatric epilepsy known as Dravet syndrome. Preliminary clinical trials assessing the safety and tolerability of the compound in children are scheduled to begin imminently.

For more information, please contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, "Cannabidiol as a potential treatment for psychosis," appears in Neuropsychopharmacology.